HCV infects approximately 2–3% of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Treatment of HCV infection with Peg-IFN in combination with ...

Please provide your email address to receive an email when new articles are posted on . HBV-infected children treated with combination PEG-INF a-2b/nucleos(t)ide analogues achieved higher HBsAg loss ...

The Emerging Markets Physician & Payer Forum report entitled Positioning of Current and Emerging Agents for Hepatitis C Virus: Physician and Payer Perspectives on the Prescribing and Patient Access ...

RAGE ligand S100A8/A9 as a novel prognostic biomarker for high-risk melanoma patients. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does not include a full text ...